Literature DB >> 12006437

Staging in lung cancer: is 3 cm a prognostic threshold in pathologic stage I non-small cell lung cancer? A multicenter study of 1,020 patients.

Angel López-Encuentra1, José Luis Duque-Medina, Ramón Rami-Porta, Agustín Gómez de la Cámara, Paloma Ferrando.   

Abstract

INTRODUCTION: Since 1974, a tumor size of 3 cm in diameter has been regarded as the prognostic threshold in the staging of bronchogenic carcinoma.
OBJECTIVE: To study the prognostic behavior of surgical-pathologic tumor size in non-small cell lung cancer (NSCLC) with complete resection.
DESIGN: Four-year multi-institutional prospective study from 1993 to 1997. PATIENTS: Consecutive cases of NSCLC in pathologic stages IA-IB (pIA-pIB) treated surgically with complete resection in hospitals belonging to the Bronchogenic Carcinoma Co-operative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S).
METHODS: The Schoenfeld procedure was used to identify different prognostic groups, considering 1 cm as the measurement unit.
RESULTS: Based on the 1,020 cases evaluated, four prognostic groups were identified: 0 to 2 cm (group A; n = 147), 2.1 to 4 cm (group B; n = 448), 4.1 to 7 cm (group C; n = 336), and > 7 cm (group D; n = 89). At 5 years, survival was 0.63 (95% confidence interval [CI], 0.58 to 0.68), 0.56 (95% CI, 0.53 to 0.59), 0.49 (95% CI, 0.46 to 0.52), and 0.38 (95% CI, 0.32 to 0.44) for groups A, B, C, and D, respectively. Differences between paired groups (log-rank) were significant: 0.0074 between groups A and B, 0.0048 between groups B and C, and 0.0034 between groups C and D.
CONCLUSIONS: In initial stages (pIA-pIB) of NSCLC, the 3-cm value was not found to behave as a prognostic threshold; in this study, four surgical-pathologic tumor size groups were identified with strong prognostic differences: from 0 to 2 cm, from 2.1 to 4 cm, from 4.1 to 7 cm, and > 7 cm.

Entities:  

Mesh:

Year:  2002        PMID: 12006437     DOI: 10.1378/chest.121.5.1515

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

Review 1.  Lung cancer screening.

Authors:  Peter J Mazzone; Tarek Mekhail
Journal:  Curr Oncol Rep       Date:  2007-07       Impact factor: 5.075

2.  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Authors:  Gary M Strauss; James E Herndon; Michael A Maddaus; David W Johnstone; Elizabeth A Johnson; David H Harpole; Heidi H Gillenwater; Dorothy M Watson; David J Sugarbaker; Richard L Schilsky; Everett E Vokes; Mark R Green
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

3.  Heterogeneity of prognostic profiles in non-small cell lung cancer: too many variables but a few relevant.

Authors:  Agustín Gomez de la Cámara; Angel López-Encuentra; Paloma Ferrando
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

4.  Previous tumour as a prognostic factor in stage I non-small cell lung cancer.

Authors:  Angel López-Encuentra; Agustín Gómez de la Cámara; Ramón Rami-Porta; José Luis Duque-Medina; José Luis Martín de Nicolás; Javier Sayas
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

5.  Relationship between tumor size and disease stage in non-small cell lung cancer.

Authors:  Fu Yang; Haiquan Chen; Jiaqing Xiang; Yawei Zhang; Jianhua Zhou; Hong Hu; Jie Zhang; Xiaoyang Luo
Journal:  BMC Cancer       Date:  2010-09-02       Impact factor: 4.430

6.  A Robust 8-Gene Prognostic Signature for Early-Stage Non-small Cell Lung Cancer.

Authors:  Ru He; Shuguang Zuo
Journal:  Front Oncol       Date:  2019-07-31       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.